0001852647-23-000003.txt : 20230831 0001852647-23-000003.hdr.sgml : 20230831 20230831150502 ACCESSION NUMBER: 0001852647-23-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230831 DATE AS OF CHANGE: 20230831 EFFECTIVENESS DATE: 20230831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spine BioPharma, Inc. CENTRAL INDEX KEY: 0001852647 IRS NUMBER: 831212524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-491149 FILM NUMBER: 231228531 BUSINESS ADDRESS: STREET 1: 505 PARK AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-583-9700 MAIL ADDRESS: STREET 1: 505 PARK AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Spine BioPharma, LLC DATE OF NAME CHANGE: 20210322 D 1 primary_doc.xml X0708 D LIVE 0001852647 Spine BioPharma, Inc. 505 PARK AVENUE, 14TH FLOOR NEW YORK NY NEW YORK 10022 212-583-9700 DELAWARE Spine BioPharma, LLC Corporation true Marc R. Viscogliosi 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Executive Officer Director Director and Chief Executive Officer of the Issuer Fran Magee 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Executive Officer Chief Technology Officer and Chief Operating Officer Thomas Bumol, PhD 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director Frank Cammisa, MD 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director John J. Viscogliosi 505 Park Avenue, 14th Floor New York NY NEW YORK 10022 Director Pharmaceuticals Decline to Disclose 06b false 2023-08-24 false true false 0 13000000 1900000 11100000 The Offering is Class B Preferred Stock. false 1 0 0 0 false Spine BioPharma, Inc. Marc R. Viscogliosi Marc R. Viscogliosi Chief Executive Officer 2023-08-29